VORICONAZOLE AS SALVAGE THERAPY IN IMMUNOCOMPROMISED PATIENTS WITH PULMONARY ASPERGILLOSIS WHO RECEIVED FIRST LINEE ANTIFUNGAL THERAPY WITH CASPOFUNGIN

被引：0
|
作者：
Simeone, E. [1 ]
Candoni, A. [1 ]
Chiozzotto, M. [1 ]
Fanin, R. [1 ]
机构：
[1] Div Hematol, Udine, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0179
引用
收藏
页码：71 / 71
页数：1
相关论文
共 50 条
  • [31] Short course of voriconazole therapy as a risk factor for relapse of invasive pulmonary aspergillosis
    Dong Hoon Shin
    Seung-Jin Yoo
    Kang Il Jun
    Hyungjin Kim
    Chang Kyung Kang
    Kyoung-Ho Song
    Pyoeng Gyun Choe
    Wan Beom Park
    Ji-Hwan Bang
    Eu Suk Kim
    Sang Won Park
    Hong Bin Kim
    Nam-Joong Kim
    Myoung-don Oh
    Scientific Reports, 10
  • [32] Shortening of voriconazole i.v. application for therapy of invasive pulmonary aspergillosis
    不详
    INFECTION, 2005, 33 (03) : 235 - 235
  • [33] Short course of voriconazole therapy as a risk factor for relapse of invasive pulmonary aspergillosis
    Shin, Dong Hoon
    Yoo, Seung-Jin
    Jun, Kang Il
    Kim, Hyungjin
    Kang, Chang Kyung
    Song, Kyoung-Ho
    Choe, Pyoeng Gyun
    Park, Wan Beom
    Bang, Ji-Hwan
    Kim, Eu Suk
    Park, Sang Won
    Kim, Hong Bin
    Kim, Nam-Joong
    Oh, Myoung-don
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [34] Voriconazole for primary therapy of proven chronic pulmonary aspergillosis: a prospective multicenter trial
    Hennequin, C.
    Cadranel, J.
    Philippe, B.
    Bergeron, A.
    Bergot, E.
    Chanez, P.
    Cottin, V.
    Jeanfaivre, T.
    Godet, C.
    Pineau, M.
    Germaud, P.
    MYCOSES, 2009, 52 : 122 - 122
  • [35] COST-EFFECTIVENESS ANALYSIS OF CASPOFUNGIN VERSUS VORICONAZOLE IN THE EMPIRICAL ANTIFUNGAL THERAPY OF FEBRILE NEUTROPENIA IN CHINA
    Wei, Y.
    Chen, Y.
    Guo, Z.
    VALUE IN HEALTH, 2016, 19 (07) : A911 - A911
  • [36] Successful Treatment of Antifungal Combination Therapy with Inhaled Liposomal Amphotericin B and Oral Voriconazole for Intractable Chronic Progressive Pulmonary Aspergillosis
    Hamada, Noboru
    Ishiga, Mitsunori
    Tanaka, Suzuka
    Ooue, Yasuhiro
    Itano, Junko
    Tanaka, Hisaaki
    Yuzurio, Shota
    Horiuchi, Takeshi
    Suwaki, Toshimitsu
    Kimura, Goro
    Tanimoto, Yasushi
    INTERNAL MEDICINE, 2021, 60 (15) : 2465 - 2468
  • [37] Clinical efficacy of sequential therapy with voriconazole on COPD patients in acute phase with pulmonary aspergillosis an effects on cytokines and pulmonary functions
    Du, J. -F.
    Chi, Y. -M.
    Song, Z.
    Di, Q. -G.
    Shi, J.
    Lv, J.
    Ma, Z. -T.
    Li, M.
    Sun, B. -H.
    Jiang, M. -M.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2018, 22 (06) : 1837 - 1842
  • [38] Breakthrough zygomycoses in patients receiving antifungal therapy with voriconazole.
    Balasubramanian, L
    Trifilio, SM
    Tallman, M
    Mehta, J
    Bennett, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 601S - 601S
  • [39] COST ANALYSIS OF VORICONAZOLE VERSUS CASPOFUNGIN FOR PRIMARY THERAPY OF INVASIVE ASPERGILLOSIS AMONG HIGH-RISK HEMATOLOGIC CANCER PATIENTS IN CHINA
    Gao, X.
    Xue, M.
    Stephens, J.
    Chen, Y.
    Haider, S.
    Charbonneau, C.
    VALUE IN HEALTH, 2015, 18 (03) : A295 - A295
  • [40] The pharmacokinetic challenge of voriconazole therapy for cerebral aspergillosis in patients treated with ibrutinib
    Rémy Nyga
    Laura Simon
    Taieb Chouaki
    Caroline Delette
    Youssef Bennis
    Cedric Joseph
    Jean-Pierre Marolleau
    Michel Slama
    Elie Zogheib
    Julien Maizel
    Critical Care, 23
12345